When given alongside chemotherapy, Tecentriq (atezolizumab) increases the percentage of people with early triple-negative breast cancer (TNBC) who show no signs of cancer during tumor removal surgery, a Phase 3 trial shows. These results were found regardless of the patient’s PD-L1 status, or the amount of the PD-L1 protein on the individual’s cancer cells. The study,…
Biogen and Eisai have submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) requesting the approval of aducanumab (BIIB037) for the treatment of Alzheimer’s disease. The submission, which was asking for priority review, had been pushed back earlier this year. The agency now has 60 days to decide whether to…
To promote brain health, the Alzheimer’s Foundation of America (AFA) is offering free online memory screenings that people can participate in from home. The confidential screenings — part of the AFA’s National Memory Screening Program — are provided Mondays and Wednesdays from 10 a.m. to 4 p.m. EST. They are conducted one-on-one through secure videoconferencing.…
AlzeCure Pharma announced positive results from its first clinical study of ACD856 for the potential treatment of Alzheimer’s disease. According to the company, ACD856 showed a good pharmacokinetic profile — namely a significantly shorter human half-life than its predecessor, ACD855 — and suitability for further clinical development as an oral medication for Alzheimer’s. Pharmacokinetics refers,…
Cryotherapy directed to the cancerous part of the prostate may be an effective and less invasive treatment option for men with intermediate-risk, unilateral prostate cancer, without the common side effects of traditional approaches, a small study suggests. The procedure was well tolerated, and 80% of the men were free of clinically significant disease at six and…
The Prostate Cancer Foundation (PCF) and Robert F. Smith, chairman and CEO of Vista Equity Partners are supporting research on a new non-invasive genetic test to determine a man’s risk of developing prostate cancer. Named the Smith Polygenic Risk Test for Prostate Cancer, the tool is part of PCF’s large initiative to reduce prostate cancer…
The American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) have released new guidelines for the diagnosis and treatment of advanced prostate cancer, the associations announced. These guidelines were developed by a panel of experts that a patient advocate. In addition to their own expertise and experience, panel…
A new risk calculator may help men with high levels of prostate-specific antigen (PSA) — a marker of prostate cancer — to decide if they should undergo a prostate biopsy to determine if they have cancer. The cancer risk calculator, developed by researchers at Kaiser Permanente Northern California, is specifically designed to calculate the risk…
Ibex Medical Analytics and LDPath have announced the rollout of the first clinical-grade artificial intelligence (AI) applications for pathology-based prostate cancer detection in the U.K. The new apps will aid in improving the accuracy and increasing the efficiency of cancer diagnostics, the companies said. Traditionally, cancer is diagnosed with the aid of a pathologist — an…
The U.S. Food and Drug Administration (FDA) has given Celyad Oncology permission to begin a Phase 1 clinical trial of CYAD-211, an investigational treatment for relapsed or refractory multiple myeloma. The trial is expected to commence by year’s end. “The FDA’s permission to begin the Phase 1 clinical trial of our lead shRNA-based allogeneic candidate…
